Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.

Hematology/oncology clinics of North America - 1 Aug 2017

Meyer Sara C

Abstract excerpt

Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells. JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone. Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Janus Kinase 2

Share to Molecular Targeted Therapy

Share to Myeloproliferative Disorders

Share to Primary Myelofibrosis

Share to STAT Transcription Factors

Source

Identifiers

PMID: 28673392
DOI: 10.1016/j.hoc.2017.04.003

Genes

JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.PMID 28673392Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.Semantic proximity Read ↗

Intrinsic resistance to JAK2 inhibition in myelofibrosis.Semantic proximity Read ↗

Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative NeoplasmsSemantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Mechanisms of drug resistance in AML.Semantic proximity Read ↗

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.Semantic proximity Read ↗

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.Semantic proximity Read ↗

Resistance to targeted therapies: delving into FLT3 and IDH.Semantic proximity Read ↗

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.